BACKGROUND: Epidemiological data on myeloid malignancies are very rare in the literature due to a lack of registration by cancer registries until 2000. The Registry of Hematologic Malignancies of the Côte d'Or Department in France has, however, steadfastly registered data on cases occurring in the Department since 1980, resulting, to date, in a database of over 5,000 cases classified according to the ICD-O-3 classification, following the most recent World Health Organization classification criteria. DESIGN AND METHODS: Twenty-five years of data on myeloid malignancies, including acute myeloid leukemia, myeloproliferative neoplasms, myelodysplastic syndromes and myelodysplastic/myeloproliferative syndromes were analyzed. World population standardized incidence rates were calculated as were as observed and relative survival. RESULTS: Incidence rates per 100,000 inhabitants/year were 2.5 for acute myeloid leukemia, 1.3 for myelodysplastic syndromes, 3.2 for myeloproliferative neoplasms and 0.6 for myelodysplastic/myeloproliferative syndromes. It was found that the incidence rate of myelodysplastic syndromes increased significantly over the period. The median overall survival is 8.9 months for patients with acute myeloid leukemia, 33.8 months for patients with myelodysplastic syndromes, 91.7 months for those with myeloproliferative neoplasms and 26.6 months for patients with myelodysplastic/myeloproliferative syndromes. Observed and relative 20-year survival rates are, respectively, 12% and 13% in acute myeloid leukemia, 2% and 6% in myelodysplastic syndromes and 20% and 34% in myeloproliferative neoplasms. CONCLUSIONS: These population-based data on myeloid malignancies are the first data collected over such a long period and provide interesting information for clinicians and public health authorities, particularly given the paucity of other long-term, population-based data from cancer registries.
BACKGROUND: Epidemiological data on myeloid malignancies are very rare in the literature due to a lack of registration by cancer registries until 2000. The Registry of Hematologic Malignancies of the Côte d'Or Department in France has, however, steadfastly registered data on cases occurring in the Department since 1980, resulting, to date, in a database of over 5,000 cases classified according to the ICD-O-3 classification, following the most recent World Health Organization classification criteria. DESIGN AND METHODS: Twenty-five years of data on myeloid malignancies, including acute myeloid leukemia, myeloproliferative neoplasms, myelodysplastic syndromes and myelodysplastic/myeloproliferative syndromes were analyzed. World population standardized incidence rates were calculated as were as observed and relative survival. RESULTS: Incidence rates per 100,000 inhabitants/year were 2.5 for acute myeloid leukemia, 1.3 for myelodysplastic syndromes, 3.2 for myeloproliferative neoplasms and 0.6 for myelodysplastic/myeloproliferative syndromes. It was found that the incidence rate of myelodysplastic syndromes increased significantly over the period. The median overall survival is 8.9 months for patients with acute myeloid leukemia, 33.8 months for patients with myelodysplastic syndromes, 91.7 months for those with myeloproliferative neoplasms and 26.6 months for patients with myelodysplastic/myeloproliferative syndromes. Observed and relative 20-year survival rates are, respectively, 12% and 13% in acute myeloid leukemia, 2% and 6% in myelodysplastic syndromes and 20% and 34% in myeloproliferative neoplasms. CONCLUSIONS: These population-based data on myeloid malignancies are the first data collected over such a long period and provide interesting information for clinicians and public health authorities, particularly given the paucity of other long-term, population-based data from cancer registries.
Authors: D C Doll; H M Taylor; Y W Yesus; C W Caldwell; S Anderson; R Madsen; Q S Ringenberg; J W Yarbro Journal: Acta Haematol Date: 1989 Impact factor: 2.195
Authors: Birgitte S Preiss; Gitte B Kerndrup; Kai G Schmidt; Anne G Sørensen; Niels-Aage T Clausen; Ole V Gadeberg; Torben Mourits-Andersen; Niels T Pedersen Journal: Br J Haematol Date: 2003-10 Impact factor: 6.998
Authors: M Hultcrantz; A Ravn Landtblom; B Andréasson; J Samuelsson; P W Dickman; S Y Kristinsson; M Björkholm; T M-L Andersson Journal: J Intern Med Date: 2020-01-11 Impact factor: 8.989
Authors: V S Hoffmann; M Baccarani; J Hasford; D Lindoerfer; S Burgstaller; D Sertic; P Costeas; J Mayer; K Indrak; H Everaus; P Koskenvesa; J Guilhot; G Schubert-Fritschle; F Castagnetti; F Di Raimondo; S Lejniece; L Griskevicius; N Thielen; T Sacha; A Hellmann; A G Turkina; A Zaritskey; A Bogdanovic; Z Sninska; I Zupan; J-L Steegmann; B Simonsson; R E Clark; A Covelli; G Guidi; R Hehlmann Journal: Leukemia Date: 2015-03-18 Impact factor: 11.528
Authors: Peter G Miller; Fatima Al-Shahrour; Kimberly A Hartwell; Lisa P Chu; Marcus Järås; Rishi V Puram; Alexandre Puissant; Kevin P Callahan; John Ashton; Marie E McConkey; Luke P Poveromo; Glenn S Cowley; Michael G Kharas; Myriam Labelle; Sebastian Shterental; Joji Fujisaki; Lev Silberstein; Gabriela Alexe; Muhammad A Al-Hajj; Christopher A Shelton; Scott A Armstrong; David E Root; David T Scadden; Richard O Hynes; Siddhartha Mukherjee; Kimberly Stegmaier; Craig T Jordan; Benjamin L Ebert Journal: Cancer Cell Date: 2013-06-13 Impact factor: 31.743
Authors: Samer A Srour; Susan S Devesa; Lindsay M Morton; David P Check; Rochelle E Curtis; Martha S Linet; Graça M Dores Journal: Br J Haematol Date: 2016-04-07 Impact factor: 6.998
Authors: Marc Maynadié; Roberta De Angelis; Rafael Marcos-Gragera; Otto Visser; Claudia Allemani; Carmen Tereanu; Riccardo Capocaccia; Adriano Giacomin; Jean-Michel Lutz; Carmen Martos; Risto Sankila; Tom Børge Johannesen; Arianna Simonetti; Milena Sant Journal: Haematologica Date: 2012-09-14 Impact factor: 9.941